We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Avidity Biosciences, Inc. today announced its collaboration with the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (FSHD CTRN) to support a natural history study for people living with FSHD called the Motor Outcomes.
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering.